Salaheddin Omran Arafa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Salaheddin Omran Arafa has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Jassim Al Suwaidi
Hamad Medical Corporation, Doha, Qatar
2 shared publications - Abdullatif Al-Khal
Hamad Medical Corporation, Doha, Qatar
1 shared publication - Abdulrahman Arabi
Hamad Medical Corporation, Doha, Qatar
1 shared publication - Ali Senosi Omrani
Communicable Diseases Center, Hamad Medical Corporation, Doha, Qatar
1 shared publication - Awad Al-Qahtani
Cardiology Department, Heart Hospital, Hamad Medical Corporation (HMC), Doha P.O. Box 3050, Qatar
1 shared publication - Charbel Abi Khalil
Department of Genetic Medicine, Weill Cornell Medicine-Qatar, Doha P.O. Box 24144, Qatar
1 shared publication
Latest Publications
- Open Access
- 2 April 2025
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 53, 100536
Comparative evaluation of radiation shielding zero gravity vs lead apron in coronary angiography and percutaneous coronary intervention
- 2 April 2025
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 53, 100536
Open AccessComparative evaluation of radiation shielding zero gravity vs lead apron in coronary angiography and percutaneous coronary intervention
- Open Access
The Outcome of COVID-19 Patients with Acute Myocardial Infarction
Objectives: Coronavirus Disease 2019 (COVID-19) is a rapidly expanding global pandemic resulting in significant morbidity and mortality. COVID-19 patients may present with acute myocardial infarction (AMI). The aim of this study is to conduct detailed analysis on patients with AMI and COVID-19. Methods: We included all patients admitted with AMI and actively known or found to be COVID-19 positive by PCR between the 4 th February 2020 and the 11 th June 2020 in the State of Qatar. Patients were divided into ST-elevation myocardial infarction (STEMI) and Non-STE (NSTEMI). Results: There were 68 patients (67 men and 1 woman) admitted between the 4 th of February 2020 and the 11 th of June 2020 with AMI and COVID-19. The mean age was 49.1±9 years, 46 patients had STEMI and 22 had NSTEMI. 38% had diabetes mellitus, 31% had hypertension, 16% were smokers, 13% had dyslipidemia, and 14.7% had prior cardiovascular disease. Chest pain and dyspnea were the presenting symptoms in 90% and 12% of patients, respectively. Fever (15%) and cough (15%) were the most common COVID-19 symptoms, while the majority had no viral symptoms. Thirty-nine (33 STEMI and 6 NSTEMI) patients underwent coronary angiography, 38 of them had significant coronary disease. In-hospital MACE was low; 1 patient developed stroke and 2 died. Conclusion: Contrary to previous small reports, in-hospital adverse events were low in this largest cohort of COVID-19 patients presenting with AMI. We hypothesize patient’s demographics and profile including younger age contributed to these findings. Further studies are required to confirm this observation. Key questions: What is already known on this subject?: COVID-19 patients may present with acute myocardial infarction (AMI). What might this study add?: Contrary to previous small reports, most COVID-19 patients presenting with AMI have significant obstructive coronary artery disease and favorable in-hospital outcome. How might this impact on clinical practice?: COVID-19 patients presenting with AMI should be treated according to the standard practice.
Open AccessThe Outcome of COVID-19 Patients with Acute Myocardial Infarction
Objectives: Coronavirus Disease 2019 (COVID-19) is a rapidly expanding global pandemic resulting in significant morbidity and mortality. COVID-19 patients may present with acute myocardial infarction (AMI). The aim of this study is to conduct detailed analysis on patients with AMI and COVID-19. Methods: We included all patients admitted with AMI and actively known or found to be COVID-19 positive by PCR between the 4 th February 2020 and the 11 th June 2020 in the State of Qatar. Patients were divided into ST-elevation myocardial infarction (STEMI) and Non-STE (NSTEMI). Results: There were 68 patients (67 men and 1 woman) admitted between the 4 th of February 2020 and the 11 th of June 2020 with AMI and COVID-19. The mean age was 49.1±9 years, 46 patients had STEMI and 22 had NSTEMI. 38% had diabetes mellitus, 31% had hypertension, 16% were smokers, 13% had dyslipidemia, and 14.7% had prior cardiovascular disease. Chest pain and dyspnea were the presenting symptoms in 90% and 12% of patients, respectively. Fever (15%) and cough (15%) were the most common COVID-19 symptoms, while the majority had no viral symptoms. Thirty-nine (33 STEMI and 6 NSTEMI) patients underwent coronary angiography, 38 of them had significant coronary disease. In-hospital MACE was low; 1 patient developed stroke and 2 died. Conclusion: Contrary to previous small reports, in-hospital adverse events were low in this largest cohort of COVID-19 patients presenting with AMI. We hypothesize patient’s demographics and profile including younger age contributed to these findings. Further studies are required to confirm this observation. Key questions: What is already known on this subject?: COVID-19 patients may present with acute myocardial infarction (AMI). What might this study add?: Contrary to previous small reports, most COVID-19 patients presenting with AMI have significant obstructive coronary artery disease and favorable in-hospital outcome. How might this impact on clinical practice?: COVID-19 patients presenting with AMI should be treated according to the standard practice.